Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Major Depressive Disorder with High Inflammation
NCT07003997Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Sep 2025
- Primary completion
- Feb 2030
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Baricitinib Arm with Placebo Arm (2 arms). Primary endpoint: Change in corticostriatal functional connectivity in reward and motor circuits at 8 weeks. Started Sep 2025; status: recruiting.
02
Drugs
baricitinib
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07003997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07003997.